⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2735522 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL7214922 | 0.97 | — | — | |
| SCHEMBL12607355 | 0.83 | — | — | |
| SCHEMBL2698963 | 0.83 | — | — | |
| SCHEMBL12607353 | 0.83 | — | — | |
| SCHEMBL1337832 | 0.81 | — | — | |
| SCHEMBL29342636 | 0.81 | THRB (0.30) | — | |
| Hydrochloric Acid SCHEMBL1785418 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL13345 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL1785868 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-11 | — | — | US | disclosed |
| EP-3753941-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Blueray Biopharma Co., Ltd. (CN) | 2020-12-23 | — | — | EP | disclosed |
| WO-2019158019-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海青煜医药科技有限公司 | 2019-08-22 | — | — | WO | disclosed |
| EP-3074389-B1 | QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES INC (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20120046276-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS AG (AT) | 2012-02-23 | — | — | US | disclosed |
| US-20120046276-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS AG (AT) | 2012-02-23 | — | — | US | disclosed |
| US-8088823-B2 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS AG (AT) | 2012-01-03 | — | — | US | disclosed |
| US-8088823-B2 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS AG (AT) | 2012-01-03 | — | — | US | disclosed |
| EP-1501495-B1 | USE OF PLEUROMUTILINS FOR THE TREATMENT OF DISORDERS CAUSED BY HELICOBACTER PYLORI | NABRIVA THERAPEUTICS AG (AT) | 2010-09-08 | — | — | EP | disclosed |
| US-7790749-B2 | Use of pleuromutilins for the treatment of disorders caused by Helicobacter pylori | NABRIVA THERAPEUTICS AG (AT) | 2010-09-07 | — | — | US | disclosed |
| US-7790749-B2 | Use of pleuromutilins for the treatment of disorders caused by Helicobacter pylori | NABRIVA THERAPEUTICS AG (AT) | 2010-09-07 | — | — | US | disclosed |
| EP-1875903-B1 | TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES | NABRIVA THERAPEUTICS AG (AT) | 2010-07-28 | — | — | EP | disclosed |
| EP-1390056-B1 | GLYCOPEPTIDE ANTIBIOTICS | WYETH CORP (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-1875903-A1 | TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES | Nabriva Therapeutics Forschungs GmbH (AT) | 2008-01-09 | — | — | EP | disclosed |
| US-20070270404-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) | 2007-11-22 | — | — | US | disclosed |
| US-20070270404-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) | 2007-11-22 | — | — | US | disclosed |